Spectrum Pharmaceuticals Company Profile (NASDAQ:SPPI)

About Spectrum Pharmaceuticals

Spectrum Pharmaceuticals logoSpectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has approximately six approved oncology/hematology products that target different types of non-Hodgkin's lymphoma (NHL), metastatic colorectal cancer, acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has two drugs in late-stage development: SPI-2012, which is being developed for chemotherapy-induced neutropenia in patients with breast cancer, and EOQUIN, which is being developed for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. It has a product portfolio consisting of both commercial-stage and development-stage products that address various cancer types. Its commercialized products include FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ and EVOMELA. Its other products include SPI-2012, POZIOTINIB and EOQUIN.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: SPPI
  • CUSIP: 84763A10
Key Metrics:
  • Previous Close: $5.89
  • 50 Day Moving Average: $4.97
  • 200 Day Moving Average: $4.74
  • 52-Week Range: $3.21 - $7.74
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.40
  • P/E Growth: 0.00
  • Market Cap: $467.09M
  • Outstanding Shares: 79,303,000
  • Beta: 1.23
Profitability:
  • Net Margins: -34.19%
  • Return on Equity: -13.92%
  • Return on Assets: -7.43%
Debt:
  • Debt-to-Equity Ratio: 0.45%
  • Current Ratio: 3.71%
  • Quick Ratio: 3.60%
Additional Links:
Companies Related to Spectrum Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Spectrum Pharmaceuticals (NASDAQ:SPPI) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $9.50 (61.29% upside)

Analysts' Ratings History for Spectrum Pharmaceuticals (NASDAQ:SPPI)
Show:
DateFirmActionRatingPrice TargetDetails
2/10/2017Jefferies Group LLCInitiated CoverageHold -> Buy$8.00View Rating Details
11/4/2016HC WainwrightReiterated RatingBuy$10.00View Rating Details
9/15/2016FBR & CoReiterated RatingBuyView Rating Details
9/15/2016RBC Capital MarketsSet Price TargetBuy$11.00 -> $10.00View Rating Details
11/5/2015Royal Bank Of CanadaLower Price TargetOutperform$13.00 -> $12.00View Rating Details
8/18/2015Roth CapitalReiterated RatingNeutral$6.00View Rating Details
(Data available from 2/23/2015 forward)

Earnings

Earnings History for Spectrum Pharmaceuticals (NASDAQ:SPPI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2017        
11/14/2016Q3 2016($0.30)($0.22)ViewN/AView Earnings Details
8/9/2016Q216($0.29)($0.05)$30.88 million$33.90 millionViewN/AView Earnings Details
5/5/2016Q1($0.32)($0.14)$28.83 million$43.90 millionViewN/AView Earnings Details
3/9/2016Q415($0.18)($0.06)$33.87 million$50.30 millionViewN/AView Earnings Details
11/4/2015Q315($0.25)($0.28)$31.87 million$28.46 millionViewN/AView Earnings Details
8/6/2015Q215($0.22)($0.01)$34.48 million$44.98 millionViewN/AView Earnings Details
5/7/2015Q115($0.06)($0.07)$48.00 million$38.60 millionViewN/AView Earnings Details
3/13/2015Q414($0.16)$0.09$48.50 million$51.70 millionViewN/AView Earnings Details
11/6/2014Q314($0.17)$0.08$45.00 million$47.99 millionViewN/AView Earnings Details
8/7/2014Q214($0.09)$0.09$41.50 million$46.90 millionViewListenView Earnings Details
5/8/2014Q114($0.22)$0.01$39.49 million$40.10 millionViewListenView Earnings Details
3/6/2014Q313($0.11)$0.05$41.96 million$41.50 millionViewListenView Earnings Details
11/12/2013Q3($0.07)($0.13)$38.70 million$42.44 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.12)($0.08)$33.41 million$33.23 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.32)($0.06)ViewN/AView Earnings Details
11/7/2012Q312$0.29$0.42$68.56 million$69.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Spectrum Pharmaceuticals (NASDAQ:SPPI)
Current Year EPS Consensus Estimate: $-1.00 EPS
Next Year EPS Consensus Estimate: $-0.92 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.36)($0.21)($0.28)
Q2 20164($0.39)($0.25)($0.32)
Q3 20162($0.34)($0.29)($0.32)
Q4 20162($0.32)($0.27)($0.30)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Spectrum Pharmaceuticals (NASDAQ:SPPI)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
12/11/2012special$0.1512/18/201212/20/201212/28/2012
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Spectrum Pharmaceuticals (NASDAQ:SPPI)
Insider Ownership Percentage: 14.50%
Institutional Ownership Percentage: 69.31%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/5/2013Anthony E Maida IIIDirectorSell5,000$12.25$61,250.00View SEC Filing  
11/12/2012Joseph Kenneth KellerCOOBuy10,000$10.95$109,500.00View SEC Filing  
11/1/2012Anthony E Maida IIIDirectorSell5,000$11.09$55,450.00View SEC Filing  
9/4/2012Anthony E Maida IIIDirectorSell5,000$12.01$60,050.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Spectrum Pharmaceuticals (NASDAQ:SPPI)
DateHeadline
News IconEquity Watch: Checking on the Levels for Spectrum Pharmaceuticals Inc (SPPI) - Rives Journal (NASDAQ:SPPI)
rivesjournal.com - February 23 at 8:11 PM
News IconAnalysts Peer Into Their Crystal Balls For Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI): Where Is It headed? - Winfield Review (NASDAQ:SPPI)
winfieldreview.com - February 23 at 8:11 PM
News IconAnalyst Target Update on Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) - Rockville Register (NASDAQ:SPPI)
rockvilleregister.com - February 23 at 8:11 PM
News IconShare Levels in Review for Spectrum Pharmaceuticals Inc (SPPI) - Baxter Review (NASDAQ:SPPI)
baxternewsreview.com - February 23 at 8:11 PM
News IconFirst Week of SPPI April 21st Options Trading (NASDAQ:SPPI)
www.stockoptionschannel.com - February 22 at 8:10 PM
News IconWatching the Technicals on Shares of Spectrum Pharmaceuticals Inc. (SPPI) - Benton Bulletin (NASDAQ:SPPI)
bentonbulletin.com - February 18 at 8:47 AM
News IconSpectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Quarterly EPS At $-0.17 - Stock Observer (NASDAQ:SPPI)
www.thestockobserver.com - February 18 at 8:47 AM
News IconSpectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Shares on the Go mid-Session - Winfield Review (NASDAQ:SPPI)
winfieldreview.com - February 15 at 6:09 AM
News IconAre Analysts Optimistic About Where Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) is Heading? - Winfield Review (NASDAQ:SPPI)
winfieldreview.com - February 15 at 6:09 AM
News IconStock Focus: Watching Shares of Spectrum Pharmaceuticals Inc. (SPPI) - BVN (NASDAQ:SPPI)
bvnewsjournal.com - February 15 at 6:09 AM
News IconLooking Ahead for Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI); Are These Shares Ready to Go Higher? - Aiken Advocate (NASDAQ:SPPI)
aikenadvocate.com - February 14 at 6:29 AM
News IconTechnical Roundup on Shares of Spectrum Pharmaceuticals Inc. (SPPI) - Baldwin Journal (NASDAQ:SPPI)
baldwinjournal.com - February 14 at 6:29 AM
News IconInvestor Radar: Focusing in on Shares of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) - Benton Bulletin (NASDAQ:SPPI)
bentonbulletin.com - February 11 at 3:27 AM
News IconSpectrum Pharmaceuticals Inc Valuation – Initial Coverage $SPPI (NASDAQ:SPPI)
www.moderngraham.com - February 10 at 4:48 AM
News IconTicker Watch: Technical Views on Shares of Spectrum Pharmaceuticals Inc. (SPPI) - Sherwood Daily (NASDAQ:SPPI)
sherwooddaily.com - January 25 at 6:10 AM
News IconStock Update: Estimates & Target in Focus for Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) - Aiken Advocate (NASDAQ:SPPI)
aikenadvocate.com - January 23 at 9:49 PM
News IconEarnings in Full Force, Analysts Take Aim at Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) - Wall Street Beacon (NASDAQ:SPPI)
wsbeacon.com - January 23 at 9:49 PM
realistinvestor.com logoSpectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) EPS Estimate At ... - RealistInvestor.com (NASDAQ:SPPI)
www.realistinvestor.com - January 23 at 8:27 AM
News IconSpectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Daily Sentiment Score At 0 - Stock Observer (NASDAQ:SPPI)
www.thestockobserver.com - January 23 at 8:27 AM
capitalcube.com logoETFs with exposure to Spectrum Pharmaceuticals, Inc. : January 20, 2017 (NASDAQ:SPPI)
www.capitalcube.com - January 21 at 1:40 AM
News IconWill The Needle Move For Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:SPPI)
wsbeacon.com - January 16 at 6:13 PM
realistinvestor.com logoSpectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) EPS Estimate At $-0.15 - RealistInvestor.com (NASDAQ:SPPI)
www.realistinvestor.com - January 16 at 1:13 PM
News IconThe Technical Case for and Against Spectrum Pharmaceuticals, Inc. (SPPI) - The USA Commerce (NASDAQ:SPPI)
theusacommerce.com - January 13 at 3:42 AM
News IconDaily Sentiment Score Of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) At 0.346 - Stock Observer (NASDAQ:SPPI)
www.thestockobserver.com - January 9 at 8:07 AM
biz.yahoo.com logoSPECTRUM PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:SPPI)
biz.yahoo.com - January 9 at 8:07 AM
News IconTop Stock With Upside & Growth Potential: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) - Prospect Journal (NASDAQ:SPPI)
prospectjournal.com - January 2 at 7:43 PM
News IconQuarterly EPS Of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) At $-0.15 - Stock Observer (NASDAQ:SPPI)
www.thestockobserver.com - December 30 at 8:21 PM
4-traders.com logoSpectrum Pharmaceuticals : Research Reports Initiation on Biotech Stocks -- Incyte, Anavex Life Sciences, Portola Pharma, and Spectrum Pharma (NASDAQ:SPPI)
www.4-traders.com - December 30 at 12:54 AM
prnewswire.com logoResearch Reports Initiation on Biotech Stocks -- Incyte, Anavex Life Sciences, Portola Pharma, and Spectrum Pharma - PR Newswire (press release) (NASDAQ:SPPI)
www.prnewswire.com - December 29 at 8:14 AM
News IconCan This Stock Gain Traction: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) - Prospect Journal (NASDAQ:SPPI)
prospectjournal.com - December 26 at 7:10 PM
News IconCompany in Focus: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) - Liberty News (NASDAQ:SPPI)
libertynewsrecord.com - December 20 at 7:48 PM
News IconChecking in on Signals for Spectrum Pharmaceuticals Inc. (SPPI) - Yankee Analysts (NASDAQ:SPPI)
yankeeanalysts.com - December 20 at 7:48 PM
News IconFocus on RSI and CCI Levels: Spectrum Pharmaceuticals Inc. (SPPI) - Yankee Analysts (NASDAQ:SPPI)
yankeeanalysts.com - December 20 at 2:47 PM
insidermonkey.com logoIs Steel Partners Holdings LP (SPLP) A Good Stock To Buy According To Other Hedge Funds? (NASDAQ:SPPI)
www.insidermonkey.com - December 20 at 2:47 PM
News IconMarket Survey: Checking on Shares of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) - Liberty News (NASDAQ:SPPI)
libertynewsrecord.com - December 17 at 1:26 AM
News IconWatching Technical Positions on Spectrum Pharmaceuticals Inc. (SPPI) - Yankee Analysts (NASDAQ:SPPI)
yankeeanalysts.com - December 17 at 1:26 AM
capitalcube.com logoETFs with exposure to Spectrum Pharmaceuticals, Inc. : December 14, 2016 (NASDAQ:SPPI)
www.capitalcube.com - December 15 at 5:36 AM
News IconCompany Focus on Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) - OIB News (NASDAQ:SPPI)
oibnews.com - December 14 at 2:06 AM
News IconUpdate on Valuation Formula's For Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) - The Business Journal (NASDAQ:SPPI)
belmontbusinessjournal.com - December 13 at 1:01 AM
insidermonkey.com logoShould You Avoid Spectrum Pharmaceuticals, Inc. (SPPI)? - Insider Monkey (blog) (NASDAQ:SPPI)
www.insidermonkey.com - December 13 at 1:01 AM
News IconWilliams %R, RSI, and ADX Update for Spectrum Pharmaceuticals Inc. (SPPI) - Yankee Analysts (NASDAQ:SPPI)
yankeeanalysts.com - December 13 at 1:01 AM
News IconShould You Avoid Spectrum Pharmaceuticals, Inc. (SPPI)? (NASDAQ:SPPI)
feedproxy.google.com - December 12 at 9:56 AM
News IconSpectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Daily Sentiment Score At 0.373 - Stock Observer (NASDAQ:SPPI)
www.thestockobserver.com - December 11 at 6:54 PM
News IconInvestor Box: Viewing Levels on Shares of Spectrum Pharmaceuticals Inc. (SPPI) - Yankee Analysts (NASDAQ:SPPI)
yankeeanalysts.com - December 10 at 7:07 PM
News IconCompany Focus on Shares of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) - Liberty News (NASDAQ:SPPI)
libertynewsrecord.com - December 9 at 7:51 PM
News IconCCI Level Check for Spectrum Pharmaceuticals Inc. (SPPI) - Yankee Analysts (NASDAQ:SPPI)
yankeeanalysts.com - December 9 at 7:51 PM
News IconSpectrum Pharmaceuticals Highlights Promising Preclinical Data Evaluating Poziotinib in Lung ... (NASDAQ:SPPI)
www.biomedreports.com - December 8 at 9:00 PM
businesswire.com logoSpectrum Pharmaceuticals Highlights Promising Preclinical Data Evaluating Poziotinib in Lung Cancer at the 17th ... - Business Wire (press release) (NASDAQ:SPPI)
www.businesswire.com - December 8 at 8:20 AM
uk.finance.yahoo.com logoSpectrum Pharmaceuticals Highlights Promising Preclinical Data Evaluating Poziotinib in Lung Cancer at the 17th IASLC World Conference on Lung Cancer (NASDAQ:SPPI)
uk.finance.yahoo.com - December 8 at 8:20 AM
stocksdaily.net logoSpectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Held $139.986 In Cash And Short-Term Investments As On 2015-12-31 - Stocks Daily (NASDAQ:SPPI)
www.stocksdaily.net - December 7 at 7:45 PM

Social

What is Spectrum Pharmaceuticals' stock symbol?

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

Where is Spectrum Pharmaceuticals' stock going? Where will Spectrum Pharmaceuticals' stock price be in 2017?

4 analysts have issued 1-year price targets for Spectrum Pharmaceuticals' stock. Their predictions range from $8.00 to $10.00. On average, they expect Spectrum Pharmaceuticals' share price to reach $9.50 in the next twelve months.

When will Spectrum Pharmaceuticals announce their earnings?

Spectrum Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March, 7th 2017.

What are analysts saying about Spectrum Pharmaceuticals stock?

Here are some recent quotes from research analysts about Spectrum Pharmaceuticals stock:

  • Jefferies Group LLC analysts commented, "SPPI is undervalued based on Rolontis' LT promise in chemotherapy-induced neutropenia. We see 50%+ share upside as Rolontis' Ph. III program is lower risk (with data in H1 2018) and we believe its profile, senior management's oncology experience, and CIN market dynamics should enable Rolontis to gain meaningful market share from Neulasta. Poziotinib in mBC/NSCLC bears watching and offers pipeline optionality. Assume at Buy and $7.50 PT." (2/10/2017)
  • According to Zacks Investment Research, "Shares of Spectrum have underperformed the Medical Drugs industry in the past one year. The company’s efforts to gain approval for Qapzola (bladder cancer) in the U.S. suffered a setback with the FDA issuing a Complete Response Letter (CRL) in Nov 2016. Any hiccup on the regulatory/development front could pull down the stock significantly. In addition, the company faces declining sales for most of its products due to intense competition. Generic threats also remain a major concern for the company. However, performance of newly launched multiple myeloma drug, Evomela, has been impressive. With the company inking out-licensing agreements for a number of products, it will now be able to focus on Evomela and the development of its pipeline candidates." (1/11/2017)

  • FBR & Co analysts commented, "This morning, before the market open, Spectrum put out a press release announcing that Evomela was approved by the FDA. Before the company put out its press release, the news of Evomela being approved by the FDA crossed the wire on Friday, March 11. Evomela was approved before its PDUFA date of May 9, 2016, so it came as somewhat of a surprise to us and investors. As a reminder, the FDA issued a CRL to Spectrum on October 23, 2015, in response to its initial NDA filing, though the CRL was not due to any clinical deficiencies identified by the FDA; rather, it was related to a Form 483 issue with one of Spectrum’s suppliers. As we previously noted, the melphalan market is only about $100 million annually." (3/15/2016)

Who owns Spectrum Pharmaceuticals stock?

Spectrum Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (6.53%), Dimensional Fund Advisors LP (2.48%), State Street Corp (2.04%), Barrow Hanley Mewhinney & Strauss LLC (0.30%), Bard Associates Inc. (0.17%) and Numeric Investors LLC (0.15%).

Who sold Spectrum Pharmaceuticals stock? Who is selling Spectrum Pharmaceuticals stock?

Spectrum Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Renaissance Technologies LLC, Two Sigma Investments LP, Bard Associates Inc. and Metropolitan Life Insurance Co. NY.

Who bought Spectrum Pharmaceuticals stock? Who is buying Spectrum Pharmaceuticals stock?

Spectrum Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Russell Investments Group Ltd., Tudor Investment Corp Et Al, Comerica Bank, Thrivent Financial for Lutherans and New York State Teachers Retirement System.

How do I buy Spectrum Pharmaceuticals stock?

Shares of Spectrum Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Spectrum Pharmaceuticals stock cost?

One share of Spectrum Pharmaceuticals stock can currently be purchased for approximately $5.89.

Spectrum Pharmaceuticals (NASDAQ:SPPI) Chart for Thursday, February, 23, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Earnings History Chart

Earnings by Quarter for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Dividend History Chart

Dividend Payments by Quarter for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Last Updated on 2/23/2017 by MarketBeat.com Staff